Author: KODIAK SCIENCES INC.

Posted Date:

March 31, 2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

KODIAK SCIENCES INC.

March 31, 2026
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

KODIAK SCIENCES INC.

March 26, 2026
Final APEX Phase 1b Clinical Results for Kodiak’s KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

KODIAK SCIENCES INC.

February 4, 2026